- Nickel-Catalyzed Asymmetric Hydrogenation for the Synthesis of a Key Intermediate of Sitagliptin
-
Nickel-catalyzed enantioselective hydrogenation of enamines leading to the efficient synthesis of 3-R-Boc-amino-4-(2,4,5-trifluorophenyl)butyric esters, the key intermediate of the blockbuster antidiabetic drug (R)-SITAGLIPTIN, is described. The sitagliptin motifs were isolated in more than 99% yield and with 75–92% ee using the earth-abundant nickel catalyst. Upon chiral resolution with (R)- and (S)-1-phenylethylamines, the partially enantioenriched (R)- and (S)-Boc-3-amino-4-(2,4,5-trifluorophenyl)butanoic acids provided >99.5% ee of the crucial sitagliptin intermediate. The asymmetric hydrogenation protocol was scaled up to 10 g with consistency in yield and ee, and has been reproduced in multiple batches.
- Sudhakaran, Shana,Shinde, Prasad G.,Aratikatla, Eswar K.,Kaulage, Sandeep H.,Rana, Priksha,Parit, Ratan S.,Kavale, Dattatry S.,Senthilkumar, Beeran,Punji, Benudhar
-
-
- Preparation method of chiral 4 - aryl - β β-amino acid derivative
-
Provided is a method for preparing a chiral 4-aryl-β-amino acid derivative. The preparation method comprises hydrogenating an enamine compound having a structure as shown in Formula III in an organic solvent in the presence of a catalyst containing a transition metal and BIBOPs. The preparation method of the present invention uses a small amount of a selected asymmetric catalyst, and has a simple operation, mild reaction conditions, a high yield, a high stereoselectivity, and better industrial application and economic values.
- -
-
Paragraph 0068-0070
(2021/11/14)
-
- A west he row sandbank chiral intermediate and asymmetric synthesis method
-
The invention relates to a sitagliptin chiral intermediate and an asymmetric synthesis method thereof. The asymmetric synthesis method comprises the steps: with 2,4,5-trifluorophenyl acetic acid as a starting material, carrying out a reduction reaction to obtain 2-(2,4,5-trifluorophenyl)ethanol, then carrying out a reaction with an oxidant, carrying out condensation of the product without separation and (R)-(+)-tert-butyl sulfinamide to obtain corresponding acetal, carrying out a reaction of the obtained product with dialkyl malonate to obtain a key chiral intermediate, hydrolyzing to obtain a corresponding organic amine, carrying out a reaction of the amine with caustic alkali and then acidifying to obtain a corresponding carboxylic acid, then carrying out condensation with 3-(trifluoromethyl)-5,6,7,8- tetrahydro-[1,2,4] triazolo[4,3-a]pyrazine hydrochloride to obtain sitagliptin tert-butyl oxanamide, and finally deprotecting with hydrochloric acid to obtain sitagliptin. The yields of all the steps are all higher, the used reagents are all conventional cheap reagents, no expensive chiral catalysts are used, the reaction conditions are quite mild, and the asymmetric synthesis method is suitable for industrialization.
- -
-
-
- Glucovance west Geleg sandbank intermediate process for the preparation of amino acid derivatives
-
The invention discloses a preparation method of a new diabetes drug sitagliptin intermediate aminobenzene butyric acid derivative. The preparation method comprises the following steps of: (1) mixing a compound shown in a formula I with R(+)-alpha-phenethyl and acetic acid to obtain a compound shown in a formula II; (2) mixing the compound shown in the formula II with sodium borohydride and protonic acid or lewis acid to obtain a compound shown in a formula III; (3) mixing the compound shown in the formula III with X to obtain a compound shown in a formula IV; (4) mixing the compound as shown in the formula IV with an inorganic base 1 to obtain a compound shown in a formula V; (5) obtaining a compound shown in a formula VI by the compound shown in the formula V; and (6) mixing the compound shown in the formula VI with an inorganic base 2 to obtain a compound shown in a formula VII.
- -
-
-
- Sitagliptin intermediate preparation method
-
The invention relates to the technical field of organic chemistry and especially relates to a sitagliptin intermediate preparation method. The invention provides a compound with a structure shown in the formula 6. The sitagliptin intermediate shown in the formula 8 and prepared from the compound with a structure shown in the formula 6 has high HPLC purity and an ee value of 99% or more.
- -
-
-
- SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF
-
The present invention relates to Sitagliptin intermediate and preparation method and use thereof. The method comprises reacting compound of formula (II) and trifluorobromobenzene with a Grignard reagent by a Grignard reaction to obtain a compound of formula (I). Compound of formula (I) is a new intermediate compound for the synthesis of Sitagliptin. Compound of formula (I) can be easily used for preparing another important intermediate compound of formula (V) for the synthesis of Sitagliptin. The structures of the compounds mentioned above are as the following:
- -
-
Page/Page column 10
(2012/08/08)
-
- SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF
-
The present invention relates to Sitagliptin intermediate and preparation method and use thereof. The method comprises reacting compound of formula (II) and trifluorobromobenzene with a Grignard reagent by a Grignard reaction to obtain a compound of formula (I). Compound of formula (I) is a new intermediate compound for the synthesis of Sitagliptin. Compound of formula (I) can be easily used for preparing another important intermediate compound of formula (V) for the synthesis of Sitagliptin. The structures of the compounds mentioned above are as the following:
- -
-
Page/Page column 7
(2012/07/27)
-
- Process for the production of sitagliptin
-
The present invention is directed to a process for the preparation of Sitagliptin, having formula (I)
- -
-
-
- Synthesis of a chiral β-amino acid derivative by a cobalt-catalysed coupling reaction
-
A chiral β-amino acid derivative was synthesised by a cobalt-catalysed alkylation of 2,4,5-trifluorophenyl magnesium bromide with the alkyl halide derivative of L-aspartic acid, using an efficient catalytic reagent: CoCl 2/TMEDA. The halide der
- Pan, Xianhua,Yu, Wansheng,Ou, Wenhua,Tao, Xiaohu,Wan, Jiaomei,Liu, Feng
-
p. 545 - 546
(2011/11/29)
-
- PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES
-
A process for producing an enantiomerically enriched, pure or enriched and essentially pure compound of Formula I [structure] wherein the R-, or S-configuration at the stereogenic center is marked with an *, which process hydrogenates an enamide compound of formula III [structure] in an organic solvent in the presence of a transition metal precursor complexed to a chiral phosphine ligand catalyst, wherein Ar is phenyl which is unsubstituted or substituted, R1 and R2 are selected from H, Cl - 8 alkyl, C5 - 12 cycloalkyl, aryl and aryl-C 1 - 2-alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a C4- r member heterocyclic πng system optionally fused with a 5- to 6- member carbocyclic or heterocyclic ring system, and the other substituents are as defined herein.
- -
-
Page/Page column 19
(2010/08/04)
-
- The synthesis of a chiral β-amino acid derivative by the Grignard reaction of an aspartic acid equivalent
-
A novel synthetic route to chiral β-amino acid derivative has been developed by a Grignard reaction of 2,4,5-trifluo- rophenyl magnesium bromide with the Weinreb amide derivative of L-aspartic acid. The aspartic equivalent was synthesised from L-aspartic
- Liu, Feng,Yu, Wansheng,Ou, Wenhua,Xu, Xiaojiong,Ruan, Libo,Wang, Xiaoke,Li, Yiming,Peng, Xijiang,Tao, Xiaohu,Mao, Jun,Wan, Jiaomei,Pan, Xianhua
-
experimental part
p. 517 - 519
(2010/12/25)
-
- PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES
-
The present invention relates to novel and improved processes for the preparation of Sitagliptin compound of formula (1) and its intermediates.
- -
-
Page/Page column 45-50
(2010/11/05)
-
- The asymmetric synthesis of Sitagliptin, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
-
An efficient asymmetric synthesis of Sitagliptin, a new DPP-IV inhibitor for the treatment of type 2 diabetes mellitus has been developed. The beta-amino acid fragment of Sitagliptin was prepared by asymmetric Michael addition of the corresponding α, β-unsaturated ester to (R)-(α-methylbenzyl) benzylamine followed by a two-step elaboration to obtain N-boc beta-amino ester. Hydrolysis of the ester and coupling with the triazolopiperazine afforded Sitagliptin after cleavage of the N-boc group and salt formation. The overall yield was 31% over nine steps.
- Liu, Feng,Yu, Wansheng,Ou, Wenhua,Wang, Xiaoke,Ruan, Libo,Li, Yiming,Peng, Xijiang,Tao, Xiaohu,Pan, Xianhua
-
experimental part
p. 230 - 232
(2010/08/04)
-
- PREPARATION OF SITAGLIPTIN INTERMEDIATE
-
Intermediate compounds in the synthesis of Sitagliptin, 3-amino-4-(2,4,5- trifluorophenyl)but-2-enoic acid alkyl ester, and amino protected-3-amino-4-(2,4,5- trifluorophenyl)but-2-enoic acid alkyl ester, and the stereoselective reduction of these compound to give Synthon I, or the amino-protected Synthon I, are provided.
- -
-
Page/Page column 16
(2009/06/27)
-
- Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors
-
Inhibitors of dipeptidyl peptidase IV (DPP-IV) have been shown to be effective treatments for type 2 diabetes. A series of β-aminoacyl-containing cyclic hydrazine derivatives were synthesized and evaluated as DPP-IV inhibitors. One member of this series, (R)-3-amino-1-(2-benzoyl-1,2-diazepan-1-yl)-4-(2,4,5-trifluorophenyl)but an-1-one (10f), showed potent in vitro activity, good selectivity and in vivo efficacy in mouse models. Also, the binding mode of compound 10f was determined by X-ray crystallography.
- Ahn, Jin Hee,Shin, Mi Sik,Jun, Mi Ae,Jung, Sun Ho,Kang, Seung Kyu,Kim, Kwang Rok,Rhee, Sang Dal,Kang, Nam Sook,Kim, Sun Young,Sohn, Sang-Kwon,Kim, Sung Gyu,Jin, Mi Sun,Lee, Jie Oh,Cheon, Hyae Gyeong,Kim, Sung Soo
-
p. 2622 - 2628
(2008/02/11)
-
- Application of the asymmetric hydrogenation of enamines to the preparation of a beta-amino acid pharmacophore
-
(3R)-3-[N-(tert-Butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoic acid 7a has been synthesized by an asymmetric hydrogenation of enamine ester 3 using chiral ferrocenyl ligands I and II in conjunction with [Rh(COD)Cl] 2. The direct reduction of 3 provides amino ester 1b in 93% ee, which was isolated as an (S)-camphorsulfonic acid salt to upgrade the enantiomeric excess to >99%. A more concise approach was developed involving the in situ protection of 1b using di-tert-butyldicarbonate. This approach provided the desired N-Boc amino ester 7b directly from the hydrogenation with 97% ee, which was upgraded to >99% ee upon crystallization.
- Kubryk, Michele,Hansen, Karl B.
-
p. 205 - 209
(2007/10/03)
-